Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

SLC22A3/OCT3 drives serotonin-mediated stemness in pancreatic cancer.

Cell reports·2026

Same author

The underexplored complexity of pancreatic cancer: Early dissemination and quiescence.

Biochimica et biophysica acta. Reviews on cancer·2026

Same author

A nanovaccine induces durable and functional MUC4-targeted T cell responses against pancreatic cancer.

Acta biomaterialia·2026

Same author

Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Same author

Rab5 nucleotide binding promotes oxidative metabolism to fuel hepatocellular carcinoma cell proliferation.

The Journal of biological chemistry·2026

Same author

Historical Perspective of HER2 Testing and Treatment in Prostate Cancer.

Current oncology (Toronto, Ont.)·2026

Search research articles

Related Experiment Video

Updated: May 9, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Emerging trends for radioimmunotherapy in solid tumors.

Maneesh Jain¹, Suprit Gupta, Sukhwinder Kaur

¹1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center , Omaha, Nebraska.

Cancer Biotherapy & Radiopharmaceuticals

|July 13, 2013

Summary

Radioimmunotherapy (RIT) shows promise for solid tumors but faces challenges. Recent strategies aim to improve RIT efficacy for solid tumors and minimal disease, including exploring alpha-particle emitters.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Experiment Videos

Last Updated: May 9, 2026

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Area of Science:

Oncology
Nuclear Medicine
Biomedical Engineering

Background:

Radioimmunotherapy (RIT) is a promising cancer treatment targeting solid tumors.
Clinical utility of RIT is limited by poor tumor uptake and pharmacokinetics.
Solid tumor RIT efficacy is hindered by tumor heterogeneity and radioresistance.

Purpose of the Study:

To review recent advancements in RIT for solid tumors.
To discuss RIT strategies for minimal residual and micrometastatic disease.
To re-evaluate previously overlooked approaches for improved tumor targeting.

Main Methods:

Literature review of recent RIT research.
Analysis of strategies to overcome RIT limitations in solid tumors.
Exploration of alpha-particle emitting radionuclides for minimal disease.

Main Results:

Significant efforts are underway to enhance RIT efficacy.
Development of localized therapy modalities for preclinical evaluation.
Revisiting historical approaches for improved tumor targeting.

Conclusions:

RIT holds potential for solid tumors and minimal disease eradication.
Overcoming pharmacokinetic and tumor heterogeneity challenges is crucial.
Novel RIT strategies, including alpha-particle therapy, are emerging.